Time to rethink haemoglobin threshold guidelines in sickle cell disease.
Br J Haematol
; 195(4): 518-522, 2021 11.
Article
en En
| MEDLINE
| ID: mdl-34131897
ABSTRACT
Alleviating anaemia in patients with sickle cell disease (SCD) is crucial in managing acute complications, mitigating end-organ damage and preventing early mortality. Some disease-modifying and curative therapies have increased haemoglobin (Hb) levels to exceed 100 g/l, a threshold above which complications from red blood cell (RBC) transfusions have occurred, raising concern about whole-blood viscosity-related complications with these therapies. Here we discuss the rationale behind this limit, the effect of viscosity on blood flow and the applicability of this Hb threshold to therapies for SCD beyond RBC transfusions.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Transfusión Sanguínea
/
Hemoglobinas
/
Anemia de Células Falciformes
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Br J Haematol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos